MARKET WIRETradingView • 1d ago
Do Options Traders Know Something About Harrow Stock We Don't?TradingView report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
Why HROW Stock slipped -0.14% Today — RQD Quant Desk Flash
$28.20 -0.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $28.14
Harrow Inc. (HROW) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.06B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HROW Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HROW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Harrow Inc. (NASDAQ: HROW) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $28.20 (-0.14% 1D, market cap $1.06B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, HROW ranks #233 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HROW compare to JANX and SPTX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HROW carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 75.1%, and ROIC of 42.9%. By comparison, JANX (Janux Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -13.8%, cap $1.07B) and SPTX (Seaport Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B). Among the 5-stock peer group, HROW leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HROW?
▼
Per HROW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001360214), Harrow Inc. generated $272.3M in revenue (+36.4% YoY), -$5.1M in net income, and $43.0M in free cash flow against $399.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (75.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $28.14 (-0.22%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 18/20 (A) • 15.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HROW)Realized 20D OHLCV Swing Band: ±10.3%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY HROW SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+18/20 pts (34% of score)
SEC XBRL FY 2025 (10-K): 15.8% FCF Margin ($43.0M FCF) & 75.1% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 65% Net Buy • Cannibal Buyback (-1.52% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$28.24-0.6% Next Q
61
Q2 (-2Q)Grade C$28.07+3.6% Next Q
58
Q3 (-1Q)Grade C$29.07-3% Next Q
56
CurrentGrade D+$28.20-0.9% Hist 90D α
53
Trajectory: C (61) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HROW Turnaround Squeeze
While HROW currently carries a cautious 53/100 (D+) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Strong cash generator (75.1% gross margin)—profits are backed by real money, not accounting tricks.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($32.41) and Max Pain ($29.61) forces dealer call-delta covering toward $57.59.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.52% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HROW• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HROW Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HROW Stock slipped -0.14% Today — RQD Quant Desk Flash
Harrow Inc. (HROW) slipped -0.14% to $28.20, trading at 4% of its 52-week range ($26.96 – $54.85). Stretched risk/reward at current multiples (43% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($26.96 – $54.85) with RSI-14 at 41.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.3% around $28.20 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 75.1% gross margin and $43.0M annual free cash flow.
Live HROW Headlines & Catalysts
MARKET WIREYahoo Finance • 1d ago
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline?Yahoo Finance report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Harrow: Q3 Needs To Prove The Turnaround Is Real (NASDAQ:HROW)Seeking Alpha report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst PredictionsSimply Wall St report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
Harrow stock hits 52-week low at 28.51 USDInvesting.com report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETIKR.com • 1d ago
Harrow Has Lost 32% in 3 Months: Here’s Why BTIG Sees 106% Upside from HereTIKR.com report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Is Harrow (HROW) Below Fair Value Based On Its Sales?Yahoo Finance report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Eye doctors can now prescribe Harrow medicines in software they already useStock Titan report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 1d ago
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 1d ago
PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow’s Eye Care PortfolioSCOTTSDALE, Ariz., November 02, 2026--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions i
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HROW)
- ✓Walkthrough of HROW's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HROW // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.85%🛡️ HOLDING TREND SUPPORT
2026-11-03O $29.99H $29.99L $28.20C $28.20VOL 335.3K
RES: $34.46SUP: $26.75SMA50: $32.41SMA200: $38.16
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HROW Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
31.7%/yr Implied 5Y Growth
vs. +36.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on HROW today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HROW. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HROW today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HROW)
Health Care Rank #233 of 1015
⚔️ JANX vs HROW Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HROW vs. JANX, SPTX, CTY, MLTX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Harrow Inc. (HROW) ranks #233 by composite RQD confidence (53/100, grade D+) and #350 by equity capitalization ($1.06B). Within this direct 5-issuer industry benchmark cohort, HROW leads on earnings valuation at N/A trailing P/E, while HROW leads on capital efficiency and profitability with 42.9% ROIC and 75.1% gross margin. HROW currently leads its immediate peer cohort in composite quantitative strength at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HROW
ACTIVE
Harrow Inc. | D+ | 53/100 | — | 75.1% | 42.9% | -0.14% | $1.06B | Benchmark Subject |
| JANX Janux Therapeutics Inc. | D- | 37/100 | — | — | -13.8% | -0.06% | $1.07B | /janx-vs-hrow → |
| SPTX Seaport Therapeutics Inc. | D | 48/100 | — | — | — | +2.09% | $1.05B | /sptx-vs-hrow → |
| CTY City Therapeutics Inc. | D | 50/100 | — | — | — | +0.82% | $1.04B | /cty-vs-hrow → |
| MLTX MoonLake Immunotherapeutics (Class A) | E | 32/100 | — | — | -35.0% | -2.63% | $1.00B | /mltx-vs-hrow → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001360214 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Harrow Inc. (HROW) reported GAAP revenue of $272.3M (+36.4% vs. FY2024 revenue of $199.6M , and +109.2% cumulative change since FY2023) , GAAP net income of -$5.1M, operating cash flow of $43.9M, and free cash flow of $43.0M (+280.6% YoY). On the balance sheet, HROW closed FY2025 with $399.5M in total assets against $0 in total debt (Altman Z-Score: 2.67, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $272.3M | -$5.1M | $43.9M | $43.0M | $399.5M | — |
| FY2024 (FY) | 2024-12-31 | $199.6M | -$17.5M | -$22.2M | -$23.8M | $389.0M | — |
| FY2023 (FY) | 2023-12-31 | $130.2M | -$24.4M | $3.8M | $3.8M | — | — |
3. HROW Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HROW stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Harrow Inc. (NASDAQ: HROW) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $28.20 (-0.14% 1D, market cap $1.06B). Pillar breakdown: Fundamental Cash Engine 18/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, HROW ranks #233 in composite RQD confidence.
How does HROW compare to JANX and SPTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HROW carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 75.1%, and ROIC of 42.9%. By comparison, JANX (Janux Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -13.8%, cap $1.07B) and SPTX (Seaport Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $1.05B). Among the 5-stock peer group, HROW leads on earnings multiple (N/A) while HROW leads on capital efficiency (42.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HROW?
Per HROW's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001360214), Harrow Inc. generated $272.3M in revenue (+36.4% YoY), -$5.1M in net income, and $43.0M in free cash flow against $399.5M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (75.1% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HROW trading relative to its 50-day, 200-day, and 52-week technical levels?
HROW last traded at $28.20 (-0.14% on volume of 742,673 shares), positioning the stock -12.99% below its 50-day simple moving average ($32.41) and -26.10% below its 200-day simple moving average ($38.16). Across its 52-week range of $26.96 to $54.85, HROW sits at the 4.4% percentile with a 14-day RSI of 41.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.3% ($25.30 to $31.10).
ROARABLE RATING BRIEF • RQD 53/100 (D+)
✓ SEC XBRL & RQD VERIFIED
HROW — Harrow Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Harrow Inc. (HROW) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $28.20 (-0.14% 1D, market capitalization $1.06B).
- Fundamental Cash Engine (18/20): Anchored by return on invested capital (ROIC) of 42.9%, gross margin of 75.1%, operating margin of 11.2%, and free cash flow yield of 3.82%.
- Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.67, Piotroski F-Score of 7/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Harrow Inc. Is a NASDAQ-listed issuer classified under the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. Per the recent news wire, the company's ophthalmic pipeline is the subject of conference-related attention. Gross margin of 75.1% and operating margin of 11.2% per the market data section indicate a high-margin product or service mix.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Harrow Inc. (HROW) reported $272.3M in annual revenue (up from $199.6M in FY2024, +36.4% YoY) and -$5.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($130.2M revenue, -$24.4M net income) through FY2025, HROW scaled operating cash flow to $43.9M and free cash flow to $43.0M, backed by $399.5M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 53/100): Strong cash generator (75.1% gross margin)—profits are backed by real money, not accounting tricks. Free cash flow yield of 3.82% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 18/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $26.96 – $54.85 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation and 33.6x EV/EBITDA against 11.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
The supply chain is NONE and no upstream or downstream links are recorded. Sector correlations, upstream dependencies, and downstream customer relationships are — Second-order bottlenecks cannot be identified from the provided sources.
- Key Question #1: Can HROW sustain or expand its 11.2% operating margin and 42.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $272.3M and free cash flow of $43.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is HROW's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
HROW Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Harrow Inc. (HROW) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 1d ago
Do Options Traders Know Something About Harrow Stock We Don't? TradingView report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Is Harrow (HROW) Undervalued On Growing Conference Buzz Around Its Ophthalmic Pipeline? Yahoo Finance report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Harrow: Q3 Needs To Prove The Turnaround Is Real (NASDAQ:HROW) Seeking Alpha report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Harrow (NasdaqGM:HROW) Stock Forecast & Analyst Predictions Simply Wall St report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
Harrow stock hits 52-week low at 28.51 USD Investing.com report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TIKR.com • 1d ago
Harrow Has Lost 32% in 3 Months: Here’s Why BTIG Sees 106% Upside from Here TIKR.com report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Is Harrow (HROW) Below Fair Value Based On Its Sales? Yahoo Finance report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Eye doctors can now prescribe Harrow medicines in software they already use Stock Titan report covering Harrow Inc. (HROW) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HROW Bull vs. Bear Conversation Board — What's Your Call at $28.20?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HROW 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $32.48 (+15.0%)
📌 Pinned Debate ROIC of 42.9% and an FCF yield of 3.82% place the cash-generation pillar at 18 of 20, the strongest component of the rating.
ROIC of 42.9% and an FCF yield of 3.82% place the cash-generation pillar at 18 of 20, the strongest component of the rating.. When you look under the hood at HROW, Fundamental Cash Engine is 18/20 with 75.1% gross margins and 42.9% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $54.85. My 12M target is $32.48.
EarningsSniper 🐂 BULL
Both sides have a point here — HROW's 12/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH
🎯 Target: $22.03 (-22.0%)
Spot @ $28.24 A 55 RQD score with an EV/EBITDA of 33.6 and weak whale 13F flow at 5 of 20 signals a Roarable Sell verdict on weak fundamentals.
Here is the bear case nobody on the bull side wants to address on HROW: A 55 RQD score with an EV/EBITDA of 33.6 and weak whale 13F flow at 5 of 20 signals a Roarable Sell verdict on weak fundamentals.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.